Helix is a population genomics company that is working to advance genomics research and integrate genomic data into clinical care.
Helix is the leading population genomics company working at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+™ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 3, 2021 | Series C | $50M | 5 | Warburg Pincus | — | Detail |
Jul 31, 2020 | Grant | $33M | 1 | National Institutes of Health | — | Detail |
Mar 1, 2018 | Series B | $200M | 7 | DFJ Growth | — | Detail |
Oct 27, 2017 | Series Unknown | $20M | 2 | Kleiner Perkins | — | Detail |
Aug 15, 2015 | Series A | $100M | 5 | Illumina | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Warburg Pincus | Yes | Series C |
National Institutes of Health | Yes | Grant |
DFJ Growth | — | Series C |
Kleiner Perkins | — | Series C |
Mayo Clinic Ventures | — | Series C |
Temasek Holdings | — | Series C |
Illumina | — | Series B |
Mayo Clinic | — | Series B |
Sutter Hill Ventures | — | Series B |
Casdin Capital | — | Series Unknown |